EPO enhances AKT activation in liver, inhibits gluconeogenesis in high fat diet fed mice and reduces liver inflammation associated with diet induced obesity (Meng et al., 2013). Here, EPO is linked to obesity due to melanocortin 4 receptor deficiency.